Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and small molecule CGRP receptor antagonists (gepants), are today approved for migraine prophylaxis with additional compounds expected to be introduced to the market soon. In this review, we consider other putative prophylactic migraine drugs in development, including compounds targeting G-protein coupled receptors, glutamate, ion channels, and neuromodulatory devices. Emergence of these new interventions could complement our current treatment armamentarium for migraine management.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Revue Neurologique |
Vol/bind | 177 |
Udgave nummer | 7 |
Sider (fra-til) | 827-833 |
ISSN | 0035-3787 |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
MA has received personal fees from AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis and Teva Pharmaceuticals. He is the principal investigator for ongoing clinical trials for AbbVie/Allergan, Amgen, and Lundbeck. He has received research grants from Lundbeck Foundation, Novo Nordisk Foundation, and Novartis. He serves as associate editor of Cephalalgia, The Journal of Headache and Pain, and Brain. He is the current President of the International Headache Society. TPD and AA-S declare that they have no competing interest.
Publisher Copyright:
© 2021 Elsevier Masson SAS
ID: 304786537